<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36742994</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2155-9899</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of clinical &amp; cellular immunology</Title><ISOAbbreviation>J Clin Cell Immunol</ISOAbbreviation></Journal><ArticleTitle>Cytokine Deficiencies in Patients with Long-COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">672</ELocationID><Abstract><AbstractText>Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID approximately three months after initial infection. These symptoms are highly variable, and the mechanisms inducing them are yet to be understood. We compared plasma cytokine levels from individuals with long-COVID to healthy individuals and found that those with long-COVID had 100% reductions in circulating levels of Interferon Gamma (IFN&#x3b3;) and Interleukin-8 (IL-8). Additionally, we found significant reductions in levels of IL-6, IL-2, IL-17, IL-13, and IL-4 in individuals with long-COVID. We propose immune exhaustion as the driver of long-COVID, with the complete absence of IFN&#x3b3; and IL-8preventing the lungs and other organs from healing after acute infection, and reducing the ability to fight off subsequent infections, both contributing to the myriad of symptoms suffered by those with long-COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Elizabeth Scp</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>ARUP Institute for Clinical and Experimental Pathology, 1950 Circle of Hope Drive, Salt Lake City, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Harry R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Pathology and Pediatrics, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ARUP Institute for Clinical and Experimental Pathology, 1950 Circle of Hope Drive, Salt Lake City, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coiras</LastName><ForeName>Mayte</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AIDS Immunopathology Unit, National Center of Microbiology, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spivak</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planelles</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI143567</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Cell Immunol</MedlineTA><NlmUniqueID>101563152</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IFN&#x3b3;</Keyword><Keyword MajorTopicYN="N">IL-8</Keyword><Keyword MajorTopicYN="N">Immune exhaustion</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36742994</ArticleId><ArticleId IdType="mid">NIHMS1854241</ArticleId><ArticleId IdType="pmc">PMC9894377</ArticleId><ArticleId IdType="pii">672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC Museum COVID-19 Timeline.   https://www.cdc.gov/museum/timeline/covid19.htm.</Citation></Reference><Reference><Citation>COVID-19 Dashboard
https://coronavirus.jhu.edu/map.html. (Accessed
June 18th 2022).</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. J. Infect. Dis 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific reports 2021;11(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int. J. Environ. Res 2021;18(5):2621.).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long covid: How to define it and how to manage it.</Citation><ArticleIdList><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588584</ArticleId><ArticleId IdType="pubmed">34780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A, Kudryavtsev I, Starshinova A, Kudlay D, Zinchenko Y, Glushkova A, et al. Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form. Pathogens 2021;10(11):1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect 2021;27(10):1507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez SR, Anderson MS, Glod&#xe9; MP, Robinson CC, Holmes KV. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome. J. Infect. Dis 2006;194(12):1697&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199878</ArticleId><ArticleId IdType="pubmed">17109341</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K, Imada Y, Kawase M, Nakagaki K, Matsuyama S, Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J. Med. Virol 2014;86(12):2146&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166330</ArticleId><ArticleId IdType="pubmed">24760654</ArticleId></ArticleIdList></Reference><Reference><Citation>Algahtani H, Subahi A, Shirah B. Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature. Case reports in neurological medicine 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864560</ArticleId><ArticleId IdType="pubmed">27239356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch. intern. med. res 2007;167(12):1312&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17592106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner PJ, Moallef P. Psychological impact on SARS survivors: Critical review of the English language literature. Can Psychol 2015; 56(1):123.</Citation></Reference><Reference><Citation>Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC neurology 2011;11(1):1&#x2013;7.).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim K, Chua HC. The psychological impact of SARS: a matter of heart and mind. Cmaj 2004;170(5):811&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC343855</ArticleId><ArticleId IdType="pubmed">14993176</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KS, Zheng JP, Mok YW, Li YM, LIU YN, Chu CM, et al. SARS: prognosis, outcome and sequelae. Respirology 2003;8:S36&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169213</ArticleId><ArticleId IdType="pubmed">15018132</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Jung SY, Lee MH, Kim MS. Assessing the presence of post-traumatic stress and turnover intention among nurses post&#x2013;Middle East respiratory syndrome outbreak: the importance of supervisor support. Workplace health &amp; safety 2020;68(7):337&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201205</ArticleId><ArticleId IdType="pubmed">32146875</ArticleId></ArticleIdList></Reference><Reference><Citation>Batawi S, Tarazan N, Al-Raddadi R, Al Qasim E, Sindi A, Al Johni S, et al. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual. Life Outcomes 2019;17(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560892</ArticleId><ArticleId IdType="pubmed">31186042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Shin HS, Park HY, Kim JL, Lee JJ, Lee H, et al. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in Middle East respiratory syndrome survivors. Psychiatry Investig 2019;16(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354037</ArticleId><ArticleId IdType="pubmed">30605995</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan O Long-term sequelae following previous coronavirus epidemics. Clin Med 2021; 21(1):e68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850177</ArticleId><ArticleId IdType="pubmed">33144403</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvignaud A, Fianu A, Bertolotti A, Jaubert J, Michault A, Poubeau P, et al. Rheumatism and chronic fatigue, the two facets of post-chikungunya disease: the TELECHIK cohort study on Reunion island. Epidemiol. Infect 2018;146(5):633&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892425</ArticleId><ArticleId IdType="pubmed">29486812</ArticleId></ArticleIdList></Reference><Reference><Citation>Foissac M, Javelle E, Ray S, Gu&#xe9;rin B, Simon F. Post-chikungunya rheumatoid arthritis, Saint Martin. Emerg. Infect. Dis;21(3):530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344282</ArticleId><ArticleId IdType="pubmed">25695499</ArticleId></ArticleIdList></Reference><Reference><Citation>Imad HA, Matsee W, Kludkleeb S, Asawapaithulsert P, Phadungsombat J, Nakayama EE, et al. Post&#x2013;chikungunya virus infection musculoskeletal disorders: Syndromic sequelae after an outbreak. Trop. med. infect 2021;6(2):52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167736</ArticleId><ArticleId IdType="pubmed">33921055</ArticleId></ArticleIdList></Reference><Reference><Citation>Javelle E, Ribera A, Degasne I, Ga&#xfc;z&#xe8;re BA, Marimoutou C, Simon F. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006&#x2013;2012. PLoS Negl Trop Dis 2015;9(3):e0003603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356515</ArticleId><ArticleId IdType="pubmed">25760632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornig M, Gottschalk CG, Eddy ML, Che X, Ukaigwe JE, Peterson DL, et al. Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome with atypical and classical presentations. Transl psychiatry 2017; 7(4):e1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5416687</ArticleId><ArticleId IdType="pubmed">28375204</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya JG, Holmes TH, Anderson JN, Maecker HT, Rosenberg-Hasson Y, Valencia IJ, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc. Natl. Acad. Sci 2017;114(34):E7150&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576836</ArticleId><ArticleId IdType="pubmed">28760971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 201; 1(1):e1400121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4465185</ArticleId><ArticleId IdType="pubmed">26079000</ArticleId></ArticleIdList></Reference><Reference><Citation>Deumer US, Varesi A, Floris V, Savioli G, Mantovani E, L&#xf3;pez-Carrasco P, et al. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): an overview. J Clin Med 2021;10(20):4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8538807</ArticleId><ArticleId IdType="pubmed">34682909</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med 2011;270(4):327&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins JB, van der Meer JW, Bleijenberg G. The Impact of Chronic Social Stress on Emotional Behavior in Mice and the Therapeutic Effect of Peripheral Mild-Heat Stimulation. The Lancet 2006;367(9507):346&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443043</ArticleId></ArticleIdList></Reference><Reference><Citation>Blundell S, Ray KK, Buckland M, White PD. Chronic fatigue syndrome and circulating cytokines: a systematic review. Brain Behav. Immun 2015;50:186&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">26148446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E, Noble A, Edgar C, Mackay A, Helliwell A, Vallings R, et al. Current research provides insight into the biological basis and diagnostic potential for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Diagnostics 2019;9(3):73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787691</ArticleId><ArticleId IdType="pubmed">31295930</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E, Ryan M, Edgar C, MacKay A, Vallings R, Tate W. Changes in the transcriptome of circulating immune cells of a New Zealand cohort with myalgic encephalomyelitis/chronic fatigue syndrome. Int J immunopathol pharmacol 2019; 33:2058738418820402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350121</ArticleId><ArticleId IdType="pubmed">30791746</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, Ashton KJ, Batovska J, Staines DR, Marshall-Gradisnik SM. High-throughput sequencing of plasma microRNA in chronic fatigue syndrome/myalgic encephalomyelitis. PLoS One 2014;9(9):e102783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169517</ArticleId><ArticleId IdType="pubmed">25238588</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow JW, Hagan S, Herzyk P, Cannon C, Behan PO, Chaudhuri A. A gene signature for post-infectious chronic fatigue syndrome. BMC med genomics 2009;2(1):1&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2716361</ArticleId><ArticleId IdType="pubmed">19555476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen CB, Als&#xf8;e L, Lindvall JM, Sulheim D, Fagermoen E, Winger A, et al. Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. J Transl Med 2017;15(1):1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5426002</ArticleId><ArticleId IdType="pubmed">28494812</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick G, Katz BZ, Fernandes H, Fletcher MA, Klimas N, Smith FA, et al. Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue. J Transl Med 2012;10(1):1&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480896</ArticleId><ArticleId IdType="pubmed">22973830</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI insight 2016;1(21).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5161229</ArticleId><ArticleId IdType="pubmed">28018972</ArticleId></ArticleIdList></Reference><Reference><Citation>Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci 2016;113(37):E5472&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027464</ArticleId><ArticleId IdType="pubmed">27573827</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A, Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of the human microbiome: persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front Pediatr 2018;6:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288442</ArticleId><ArticleId IdType="pubmed">30564562</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano E, Watanabe Y, Kataoka Y. Insights into metabolite diagnostic biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome. Int. J. Mol. Sci 2021; 22(7):3423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8037376</ArticleId><ArticleId IdType="pubmed">33810365</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomas C, Brown A, Strassheim V, Elson J, Newton J, Manning P. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS One 2017;12(10):e0186802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655451</ArticleId><ArticleId IdType="pubmed">29065167</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vega WC, Herrera S, Vernon SD, McGowan PO. Epigenetic modifications and glucocorticoid sensitivity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). BMC med genomics 2017;10(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324230</ArticleId><ArticleId IdType="pubmed">28231836</ArticleId></ArticleIdList></Reference><Reference><Citation>Navaneetharaja N, Griffiths V, Wileman T, Carding SR. A role for the intestinal microbiota and virome in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)?. J Clin Med 2016. Jun 6;5(6):55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4929410</ArticleId><ArticleId IdType="pubmed">27275835</ArticleId></ArticleIdList></Reference><Reference><Citation>Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 2016;4(1):1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918027</ArticleId><ArticleId IdType="pubmed">27338587</ArticleId></ArticleIdList></Reference><Reference><Citation>Newberry F, Hsieh SY, Wileman T, Carding SR. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome?. Clin Sci 2018;132(5):523&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5843715</ArticleId><ArticleId IdType="pubmed">29523751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr Virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Front immunol 2021:4637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E, Reshkova V, capital K. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic small ie, Cyrillicncephalomyelitis/chronic fatigue syndrome. J Med Virol 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza ME. Myalgic encephalomyelitis/chronic fatigue syndrome: the human herpesviruses are back!. Biomolecules 2021; 11(2):185.).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes Rivera M, Mastronardi C, Silva-Aldana CT, Arcos-Burgos M, Lidbury BA. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics 2019;9(3):91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787585</ArticleId><ArticleId IdType="pubmed">31394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins TB, Pasi BM, Litwin CM, Hill HR. Heterophile antibody interference in a multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human serum. Clin Diagn Lab Immunol 2004;11(2):325&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC371198</ArticleId><ArticleId IdType="pubmed">15013983</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins TB, Burlingame R, von M&#xfc;hlen CA, Jaskowski TD, Litwin CM, Hill HR. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 2004;11(6):1054&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524771</ArticleId><ArticleId IdType="pubmed">15539505</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Shahjin F, Cohen JD, Hasan M, Machhi J, Chugh H, et al. The immunopathobiology of SARS-CoV-2 infection. FEMS Microbiol Rev 2021; 45(6):fuab035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632753</ArticleId><ArticleId IdType="pubmed">34160586</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov 2019;5(1):1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549181</ArticleId><ArticleId IdType="pubmed">31231549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Ghosh S. Toll-like receptor&#x2013;mediated NF-&#x3b1;B activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 200;107(1):13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC198554</ArticleId><ArticleId IdType="pubmed">11134172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryabkova VA, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: Cytokine storm&#x2013;The common denominator and the lessons to be learned. Clin Immunol 2021;223:108652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832378</ArticleId><ArticleId IdType="pubmed">33333256</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams ES, Martins TB, Hill HR, Coiras M, Shah KS, Planelles V, et al. Plasma cytokine levels reveal deficiencies in IL-8 and gamma interferon in Long-COVID. medRxiv 2022.</Citation></Reference><Reference><Citation>Nguyen T, Russell J. The regulation of FasL expression during activation-induced cell death (AICD). Immunology 2001;103(4):426&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783263</ArticleId><ArticleId IdType="pubmed">11529932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Life sci 2020; 257:118102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367812</ArticleId><ArticleId IdType="pubmed">32687918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020;53(3):368&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Investig 1989;84(4):1045&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC329758</ArticleId><ArticleId IdType="pubmed">2677047</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. Cell Mol Immunol 2020;17(5):433&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192912</ArticleId><ArticleId IdType="pubmed">32238918</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenborn JR, Wilson CB. Regulation of interferon-&#x3b3; during innate and adaptive immune responses. Adv. Immunol 2007; 96:41&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati K, Guhathakurta S, Joshi J, Rai N, Ray AJ. Cytokines and their role in health and disease: a brief overview. Moj Immunol 2016;4(2):1&#x2013;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>